Visual inspection with acetic acid for detection of high grade lesion in atypical squamous cells and low grade squamous intraepithelial lesions from cervical Pap smear by Pothisuwan, Methasinee et al.
Objective: To evaluate the value of visual inspection with acetic acid (VIA) test to detect high grade lesion in women with 
atypical squamous cells or low grade squamous intraepithelial lesions cervical cytology.
Methods: Women with atypical squamous cells or low grade squamous intraepithelial lesions who were scheduled to undergo 
colposcopy at Vajira Hospital and met inclusion criteria were included. All participants underwent VIA test prior to usual steps 
of colposcopy. The VIA results were interpreted as positive or negative using the criteria by the International Agency for Cancer 
Research. The standard colposcopic examination and appropriate investigations for cervical pathology were then continued. 
The diagnostic values of VIA test including sensitivity, specificity, positive predictive value, and negative predictive value were 
determined using high grade lesion including cervical intraepithelial neoplasia 2-3 and squamous cell carcinoma as a threshold.
Results: Total of 106 women was included. The VIA test was positive in 33 women (31.1%) and negative in 73 women (68.9%). 
Among the women with VIA test positive, 14 had high grade lesion (42.4%) while 19 had no significant lesions. Only 2/73 (2.7%) 
cases with negative VIA test had high grade lesion (both had cervical intraepithelial neoplasia 2). The sensitivity, specificity, 
positive predictive value and negative predictive value with 95% confidence interval were 87.5% (81.2 to 93.8%), 78.8% (71.1 to 
86.7%), 42.4% (33.0 to 51.8%), and 97.2% (94.2 to 1.0%) respectively.
Conclusion: VIA as the intermediate test in atypical squamous cells and low grade squamous intraepithelial lesions cytology 
may reduce the necessity to refer some women for colposcopy.
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INTRODUCTION
Cervical cancer is the second most common gynecologic can-
cer world  wide, accounting for 13% of all female cancers in de-
velo  ping countries [1]. In Thailand, cervical cancer is the most 
co  mmon gynecologic cancer with the incidence rate of 29.2 
per 100,000 women per year, and is also the most common 
cause of death with the mortality rate of 15.2 per 100,000 
women per year [1]. Cervical cytologic screening has an im-
portant role in early detection of pre-invasive or invasive cer  vi-
cal lesions which usually have excellent treatment out  comes, 
therefore, resulting in reduced mortality rate. 
The Bethesda system [2] has categorized abnormal cervical 
cy  tology of squamous epithelium into atypical squamous cells 
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(ASC), low grade squamous intraepithelial lesions (LSIL), high 
grade squamous intraepithelial lesions (HSIL), and squa  mous 
cell carcinoma (SCC). HSIL and SCC generally have high risk of 
underlying histopathology of high grade lesions (HGL) inclu  ding 
CIN 2-3 and invasive cancer requiring definite investigation 
and management. Unlike HSIL and SCC, ASC and LSIL usually 
represent low risk pathology e.g., reactive/in  fla  mma  tion or 
low grade lesions (LGL) including cervical in  tra  epithelial neo-
plasia (CIN) 1 and human papillomavirus (HPV) that can ex-
pectant management. However, both ASC and LSIL also have 
definite risk of harboring HGL albeit at much lower rates than 
HSIL or SCC. The incidence of HGL varies in ASC according to 
its sub  types of ASC: ASC, of undetermined significance (ASC-
US) and ASC, cannot exclude HSIL (ASC-H). For ASC-US, the 
incidence of CIN 2-3 and SCC ranged from 2-13% and 0-2%, 
respectively [3-6]. These incidences are much higher for ASC-
H and LSIL. The CIN 2-3 and SCC could be identified in 25-75% 
and 0-8% of ASC-H respectively [7-9], and in 15-41% or up to 
5% of LSIL [10-13].
The American Society for Colposcopy and Cervical Pathol-
ogy (ASCCP) [14] has recommended triage management of 
ASC-US. HPV-DNA testing is more preferred than other two 
alterna  tives [8,15]. However, HPV testing may not be practical 
in low resource settings including some areas of Thailand due 
to its high cost and requirement of high technology to process 
the test. A follow-up cytology test will make women anxious 
and some may have a poor compliance for a follow-up visit. 
Colposcopy, as another one option, requires experienced 
operators who are limited in numbers, leading to a long wait-
ing time. With these restrictions added with the possibility of 
HGL in women with ASC or LSIL, a simple cost-effective means 
to identify HGL will be useful. Particularly in a very limited 
resource, any other means to screen and probably to treat 
women with sus  picious lesions in the same setting might be 
ideal. Among these, vi  sual inspection with acetic acid (VIA) is 
probably the most common method. Many studies reported 
achievement of VIA as a pri  ma  ry screening test [16-21].
The advantages of the VIA are its low cost, being able to be 
carried out by trained paramedical personnel, and a relatively 
high sensitivity. The sensitivity to detect HGL ranged from 
61 to 100% [20-25] while the specificity, positive predictive 
value (PPV), and negative predictive value (NPV) were 36-
98% [20-25], 9-44% [19,22,23,26], and 88-100% [19,22,23,26], 
respectively. Another obvious benefit is its immediate results 
from the clinical impression leading to a proper counselling 
and a possibility of the “see and treat” approach. This certainly 
can reduce the problem of a loss to follow-up which is espe  cially 
common in an outreached area. The main limitation is false-posi-
tive results from the VIA which may lead to overtreatment. 
We aim to evaluate the value of VIA as an intermediate test to 
detect any HGL for women with ASC or LSIL cervical cytology 
from Pap smear. This will add information to guide for a cli  ni-
cal practice particularly in settings which have limi  ted resour-
ces as in some areas of our country as well as other countries 
with similar financial background or limited availa  bility of 
heal  th service sectors. 
MATERIALS AND METHODS
This study was conducted after approval by an ethics co-
mmi    ttee of the institution. Inclusion criteria were women who 
had cervical cytologic diagnoses of ASC or LSIL and were sched-
uled for colposcopic examination at gynecologic onco  logy 
out-patient clinic at Faculty of Medicine Vajira Hospital from 
July 1, 2010 to February 28, 2011. Women who had his  tory of 
cervical cancer or pre-invasive cervical lesions, had hysterec-
tomy, were pregnant, or had an incomplete medical record 
were excluded. 
Sample size was obtained based on 83% sensitivity of VIA to 
detect HGL in prior report [24] and maximum allowable error 
of 15%. With an a error of 5% and the prevalence of HGL in 
ASC and LSIL Pap smear of 25% (statistical data of the institu-
tion in the past 3 months), sample size of 106 women was 
required. 
In a standard colposcopic procedure, the cervix was exa  min  ed 
under colposcopic examination by a gynecologic oncolo  gi  st 
or fellows in training for any lesions especially abnormal vas-
cular pattern before an application of 3-5% acetic acid. For a 
woman with satisfactory colposcopic examination (all trans-
formation zone was totally visualized), any acetowhite areas 
were biopsied for histopathologic examination (colposcopic 
direc  ted biopsy [CDB]). In any case of unsatisfactory colpos  co-
py or there was no gross ectocervical abnormality, an endo-
cervical curettage (ECC) would be carried out. Women who 
had satisfactory colposcopy with no suspicious lesions over 
ecto and endo-cervices were defined as “normal colpos  copy” 
and were schedule for a follow-up Pap smear. 
In our study to evaluate the clinical performance of the vi  su  al 
inspection of cervix after application of acetic acid or so called 
“Vi  sual Inspection with Acetic Acid or VIA” test, every woman 
was informed that the procedure is a crucial step in rou  tine col-
poscopic examination. One of the researchers (MP), who had 
been well trained and was skilled in colposcopic procedure, 
per  formed a careful inspection of the cervix by naked-eyes 
after acetic acid application. The sites and characteristics of the 
lesions were mapped and the diagnosis of the VIA test before 
proceeding to the next step of investigation. The VIA results were VIA for detection of high grade lesion in abnormal Pap smear
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interpreted as positive or negative by using the criteria of the 
International Agency for Cancer Re  search [27]. The standard 
colposcopic examination and appro  priate investigations were 
proceeded by another gyne  cologic oncologist blinded to the 
findings from the VIA tests. Management for the women was 
provided according to the results of a primary histologic diag-
nosis from tissue bio  psy obtained by CDB and/or ECC. Women 
with normal or in  fla  mmatory histology or lesion of CIN 1 were 
scheduled for a follow-up cytology. Any women with lesions 
of CIN 2-3 or worse were classified as HGL and would undergo 
cervical coni  zation by loop electrosurgical exci  sion procedure 
(LEEP) or cold knife conization as appro  priate. Hysterectomy 
was performed as indicated by the seve  rity of lesions identi-
fied from the conization specimen or other associated gyne-
cologic pathologic findings.
Clinical and pathological data of the women were retrieved 
from the out-patient charts and the archives of the Anatomi-
cal Pathology Department. Data collected were: age, meno-
pausal status, marital status, parity, cervical cytology, the result 
of VIA test, and the definite cervical histology. Histopathology 
referred to the most severe histologic diagnosis from CDB, 
ECC, LEEP, or hysterectomy. Data were analyzed by parametric 
and nonparametric statistics, using SPSS ver. 11.5 (SPSS Inc., 
Chicago, IL, USA). Descriptive statistics were used for demo-
graphic data and summarized as frequencies, percentages, 
means with standard deviation, or median with ranges. Differ-
ences between variables were evaluated with the chi-square 
or Fisher-exact test as appropriate. The primary outcome was 
considered significant only if the p≤0.05.
The diagnostic values of VIA test including sensitivity, speci-
ficity, positive predictive value, and negative predictive value 
were determined by comparing the results of the VIA test and 
the final histopathology which was used as the gold standard. 
HGL, which had clinical impact requiring prompt manage-
ment, was set as a cut-off point of reference. 
RESULTS
During the study period, 6,261 women had cervical cyto-
logic Pap smear in our institute. Cytologic diagnosis of ASC 
was identified in 66 women (1.1%) and LSIL in 65 (1.1%). From 
131 women, 25 were excluded due to: history of pre-invasive 
cervical lesions and cervical cancer (15 women), had prior hys-
terectomy (6 women), were pregnant (two women), and were 
lost of follow-up after cervical tissue biopsies (two women). 
A total of 106 women with ASC or LSIL cytology met all inclu-
sion criteria and were included in the study. Mean age of the 
women was 38.4±12.8 years. Majority of the women were 
premenopausal and multiparous, with a median parity of 1.6 
(range, 0 to 8). Median interval time from Pap smear until VIA 
and colposcopy was 6.8±3.4 weeks (range, 1.9 to 19.9 weeks). 
There were 55/106 (51.9%) women with cytologic diagnosis 
of ASC and 51/106 (48.1%) with LSIL. 
The clinical characteristics of the women in the study are 
shown in Table 1. Nearly half of the women (49.1%) who had 
ASC or LSIL were asymptomatic and had Pap smear test as 
a general health screening. Among women who had symp-
toms and sought for medical consultation, abnormal vaginal 
discharge and pelvic pain were the two common complaints 
(15.1% for each). 
From all 106 women included in the study, the VIA test was 
interpreted as positive in 33 women (31.1%) and negative 
VIA in 73 women (68.9%). From colposcopic examination, 75 
(70.8%) had satisfactory colposcopy while 31 women (29.2%) 
had unsatisfactory results. Thirteen women had no suspicious 
lesions from the colposcopic examination and were sched-
uled for follow-up Pap test at 6 months. CDB or ECC were 
performed in 76 (71.7%) and eight women (7.5%) respectively. 
Nine women (8.5%) had both CDB and ECC in the same set-
ting. Thirteen women subsequently underwent LEEP based 
Table 1. Clinical characteristic features of women with ASC and LSIL 
(n=106)
Characteristics No. (%)
Age (yr) (mean±SD) 38.4±12.8
  ≤45 79 (74.5)
  >45 27 (25.5)
Parity
  0 23 (21.7)
  ≥1 83 (78.3)
Menopausal status
  Premenopause 88 (83.0)
  Postmenopause 18 (17.0)
Anti-HIV
  Negative 82 (77.4)
  Positive 24 (22.6)
Cervical cytology
  ASC-US 47 (44.3)
  ASC-H 8 (7.5)
  LSIL 51 (48.2)
Colposcopy
  Unsatisfactory 31 (29.2)
  Satisfactory 75 (70.8)
ASC, atypical squamous cells; LSIL, low grade squamous intraepithelial 
lesions; ASC-US, ASC of undetermined significance; ASC-H, ASC cannot 
exclude HSIL; HSIL, high grade squamous intraepithelial lesions.Methasinee Pothisuwan, et al.
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on the primary histologic diagnosis from biopsy or ECC as 
CIN-2 (seven cases) or CIN-3 (six cases). One woman who was 
found from LEEP specimen to have early stromal invasion (2 
mm) ultimately had simple hysterectomy as well as the other 
three women who had biopsy results of only CIN-1 but had 
co-incidental pathology of myoma uteri or adenomyosis. 
From 106 cases with cytologic diagnoses of ASC or LSIL, nor-
mal colposcopy and unremarkable histology/histopathology 
(negative for malignancy, endocervical polyp, or cervicitis) 
were found in 32 women (30.2%) while CIN 1 was found 58 
wo  men (54.7%). Aside from one case with invasive can  cer, 
HGL or CIN 2-3 was found in 15 women (14.2%). The his  to  lo-
gy/histopathology of women with ASC and LSIL in our study 
are shown in Table 2. Among the 33 women with VIA test 
positive, 14 had HGL (42.4%) while 19 had no significant le-
sions (false positive cases, 57.6%): no pathology (one case), 
cer  vicitis/polyp (five cases), or CIN-1 (13 cases). From 73 wo-
men with VIA test negative, only two (2.7%) had HGL (false 
negative cases, 2.7%); both of them had histopathology of CIN 
2. Other negative VIA cases had negative pathology (17 cases), 
only cervicitis (8 cases), or CIN-1 (27 cases). Table 3 shows his-
to  logy/histopathology of women according to the VIA results. 
When we evaluated the histopathology of women accord-
ing to their cytology stratified by the VIA results. We found 
that women who had higher degree of abnormal cytology 
(from ASC-US to ASC-H to LSIL) and VIA positive were directly 
associated with HGL. Histology/ histopathology of women ac-
cording to their cytology and VIA test are shown in Table 4. 
The diagnostic values of VIA using HGL as the cut-off level; 
the sensitivity, specificity, positive predictive value, and nega-
tive predictive value with their 95% confidence intervals were 
87.5% (81.2-93.8%), 78.8% (71.1-86.7%), 42.4% (33.0-51.8%), 
and 97.2% (94.2-1.0%), respectively. 
DISCUSSION 
During the study period, the prevalence of either ASC or LSIL 
in our institute was 1.1% (for each) which was in the ranges 
as had been reported in other studies from 1.0-4.5% [3,28,29] 
and 0.3-1.6%, [13,28,29] respectively. 
The prevalence of ASC and LSIL during the limited study pe-
ri  od of our study was concordant to our prior reports by Lim-
pvanuspong et al. [3] and Khuakoonratt et al. [13] who identi-
fied 1.7% prevalence of ASC (830/46,680 women who had 
Pap smear from 2003 to 2006) and 0.9% LSIL (691 from 72,087 
women from 2001 to 2005). Both studies evaluated the rates 
Table 2. Histology/histopathology of women with cytologic diagno-





ASC 22 (40.0) 27 (49.1)  6 (10.9)
   ASC-US 18 (38.3) 25 (53.2) 4 (8.5)
   ASC-H 4 (50.0) 2 (25.0) 2 (25.0)
LSIL 10 (19.6) 31 (60.8) 10 (19.6)
Total 32 (30.2) 58 (54.7) 16 (15.1)
ASC, atypical squamous cells; LSIL, low grade squamous intraepithelial 
lesions; LGL, low grade lesion including cervical intraepithelial 
neoplasia (CIN) 1 and human papillomavirus; HGL, high grade lesion 
including CIN 2-3 and carcinoma; ASC-US, ASC of un  determined 
significance; ASC-H, ASC cannot exclude HSIL; HSIL, high grade 
squamous intraepithelial lesions.
*Normal included 13 women who had normal colposcopic findings.







VIA negative 26 (35.7) 45 (61.6) 2 (2.7)
VIA positive 6 (18.1) 13 (39.4) 14 (42.5)
Total 32 (30.2) 58 (54.7) 16 (15.1)
VIA, visual inspection with acetic acid; LGL, low grade lesion including 
cervical intraepithelial neoplasia (CIN) 1 and human papillomavirus; 
HGL, high grade lesion including CIN 2-3 and carcino  ma. 
*Normal included 13 women who had normal colposcopic findings.
Table 4. Histology/histopathology of women according to cytology 




polyp (%) LGL (%) HGL (%)
ASC-US
    VIA negative 13 (37.1) 21 (60) 1 (2.9)
    VIA positive 5 (41.7) 4 (33.3) 3 (25.0)
ASC-H
    VIA negative 3 (75.0) 1 (25.0) 0
    VIA positive 1 (25.0) 1 (25.0) 2 (50.0)
LSIL
    VIA negative 10 (29.4) 23 (67.6) 1 (2.9)
    VIA positive 0 8 (47.1) 9 (52.9)
Total 32 (30.2) 58 (54.7) 16 (15.1)
VIA, visual inspection with acetic acid; LGL, low grade lesion including 
cervical intraepithelial neoplasia (CIN) 1 and human papillomavirus; 
HGL, high grade lesion including CIN 2-3 and carcinoma; ASC, atypical 
squamous cells; ASC-US, ASC of undetermined signi  fi  can  ce; ASC-H, 
ASC cannot exclude HSIL; HSIL, high grade squamous intra  epithelial 
lesions; LSIL, low grade squamous intraepithelial lesions.
*Normal included 13 women who had normal colposcopic findings.VIA for detection of high grade lesion in abnormal Pap smear
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of HGL and cancer in women with cervical cytology of ASC or 
LSIL. One demonstrated 9.1% of HGL and 0.9% invasive can-
cer from 287 women with ASC [3] while another found 15.0% 
HGL and 1.3% invasive cancer from 226 women who had LSIL 
[13]. Since the majority of ASC or LSIL has a final histologic di-
agnosis of only LGL, an immediate investigation or treatment 
may be delayed. Submitting all women with low risk cytologic 
diagnoses (ASC, LSIL) to colposcopy may not be possible or 
inconvenient. This is especially true in a scenario when the 
number of colposcopists is limited and the privilege must be 
given to the more severe cytologic lesions. Nevertheless, be-
cause of the real existence of HGL in these ASC and LSIL, other 
means such as VIA to exclude HGL is a reasonable alternative 
option. The advantages of VIA are low cost, real time result, 
and can be achieved by trained paramedical workers. These 
render it suitable in low resource areas. Few studies used VIA 
in adjunct with the Pap test as a screening test to detect HGL, 
sensitivity of the two combined methods was improved com-
pared to Pap test only [23,30].
Prevalence of positive VIA test depends on the characteristic of 
the population studied e.g., asymptomatic women or sympto-
matic; co-incidental pathology of cervical dysplastic lesions and 
cervicitis or inflammation; cervical anatomy or area of transfor-
mation zone which is affected by age or menopausal status; 
or parity [31]. We found VIA positive in 33% which was higher 
than 10-16% reported in other studies which generally used 
VIA as an alternative option for primary screening test in the 
general normal population [32]. This was because our study 
evaluated VIA in a different setting, as the secondary test in 
women with mild cytologic abnormalities of ASC and LSIL. 
A few meta-analysis reports including several studies of VIA 
found various diagnostic performances of VIA [33-35]. The 
sensitivity and the specificity of VIA ranged from 72-84% and 
79-85%, respectively. The differences might lie with the sub-
jects studied (with or without gynecologic symptoms), differ-
ent thresholds, or different confirmatory diagnostic tests. One 
recent meta-analysis by Sauvaget et al. [36], including only 
studies with histologic confirmation, reported high diagnostic 
performance of VIA to detect cervical lesions using HGL as the 
threshold [36]. The sensitivity of VIA for cervical cancer screen-
ing was 80% while the specificity was 92%. Since all of their re-
viewed studies were intended for screening in asymptomatic 
women, the PPV demonstrated in this review was only 10% 
[36]. The authors found that the region or place of screening, 
study period, size of study population, and capacity of the 
screeners (health worker, nurse or physician) had no effect on 
VIA accuracy. In our study, VIA as a subsequent test in ASC and 
LSIL cytology to detect HGL had high sensitivity and NPV at 
87.5% and 97%, respectively. Only two cases (with cytologic 
diagnosis of ASC-US and LSIL) had false-negative VIA. The final 
histology was only CIN 2. While all cases with HGL including 
the one case of invasive cancer (with ASC-H cytology) which 
had positive VIA. As we found the prevalence of HGL was 
higher in women with higher degree of cytologic abnormali-
ties especially when the VIA test was positive, special atten-
tion to look for HGL is warranted in these subgroups.
From previous studies, the false-positive VIA results were due 
to inappropriate light source, an inadequate trained or experi-
ence of the observer, and the presence of cervical inflamma-
tion/ infection or metaplasia [21]. These factors may lead to an 
overtreatment if a see and treat policy is applied. Our setting 
for the VIA test is considered as optimal, yet, the false positive 
rate in our study was high at 58% (19 cases). Approximately 
15% of these false positive cases had inflammation/ polyps 
while 39% had CIN 1 (Table 3). Aside from the former group 
with obvious inflammation which can cause a false positive 
VIA, we did not know whether the latter group of CIN 1 also 
had associated metaplasia/ inflammation or the dysplastic le-
sion itself can cause positive VIA. For any reasons, these condi-
tions should be aware of, especially in a circumstance of the 
see and treat approach.
With the high sensitivity and specificity of VIA test in ASC 
and LSIL to detect HGL found in our study, this may serve as 
an intermediate test in women with mild abnormal Pap smear 
of ASC or LSIL. Women who are not at high risk for HGL (ASC 
or LSIL with negative VIA test) may undergo a follow-up Pap 
test while the women who are at high risk (ASC or LSIL with 
positive VIA test) must directly have colposcopy. The reduced 
number of women who must undergo colposcopic examina-
tion may be practical in settings when the women decline or 
not ready for a referral at the moment, where there is no or 
only limited number of colposcopists, and when HPV-DNA 
testing is not possible. Further studies in more numbers of 
women will definitely confirm the safety of this alternative op-
tion in women with abnormal Pap smears.
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